期刊
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
卷 26, 期 15, 页码 3562-3566出版社
PERGAMON-ELSEVIER SCIENCE LTD
DOI: 10.1016/j.bmcl.2016.06.021
关键词
Tyrosine Threonine Kinase (TTK); Monopolar spindle 1 kinase (Mps1); Antimitotic; Inhibitor; Cancer
资金
- Canadian Institutes of Health Research
- Princess Margaret Cancer Foundation
TTK/Mps1 is a key kinase controlling progression of cell division via participation in the mitotic spindle assembly checkpoint and is overexpressed in a number of human cancers. Herein we report the discovery of 4-(4-aminopyrazolo[1,5-a][1,3,5]triazin-8-yl) benzamides as a potent, novel class of TTK inhibitors. The series was identified by means of bioisosteric replacement of the related imidazopyrazine and imida-zopyridazine scaffolds. Optimization led to the identification of compounds with excellent potency (K-i = 0.8 nM) and exceptional kinase selectivity. The SAR indicates a strong dependence of activity on the presence of the N-cyclopropyl-2-methylbenzamide moiety delineating the geometry for 11/2 type kinase inhibitor. Molecular modeling indicates the extensive and optimal contacts, mediated through H-bonds and hydrophobic interactions, are responsible for the selectivity and potency of the inhibitors. The compounds demonstrate a strong anti-proliferative activity in a panel of human cancer cell lines (HCT116 GI(50) < 15 nM) and good rodent pharmacokinetics (oral %F 97%). (C) 2016 Elsevier Ltd. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据